Contemporary targeted therapies in rheumatology /
Saved in:
| Imprint: | London : Informa Healthcare ; Boca Raton, FL : Distributed in North America by Taylor & Francis, 2007. |
|---|---|
| Description: | xiv, 633 p. : ill. |
| Language: | English |
| Subject: | |
| Format: | E-Resource Print Book |
| URL for this record: | http://pi.lib.uchicago.edu/1001/cat/bib/7529315 |
Table of Contents:
- Section I. Cells and cell surface receptors
- 1. T cells - overview - Update
- 2. Co-stimulation: a. CD80/86 - CD28 , CTLA-4
- 3. Regulatory T cells
- 4. B Cell Antigen Receptor Signalling and Autoimmunity
- 5. Plasma cells
- 6. Targeting B lymphocyte stimulator (BLyS) in immune-based rheumatic diseases: a therapeutic promise waiting to be fulfilled
- 7. Macrophages - overview - update
- 8. Dendritic cells
- 9. Toll-like receptors
- 10. Cadherins
- 11. Complement and pregnancy loss
- 12. Osteoclasts
- 13. Cell contact dependence of inflammatory events
- Section II. Cytokines, chemokines and other effector molecules
- 14. Update on TNFa
- 15. Targeting Interleukin-1 in Rheumatic Diseases - Update
- 16. Update on IL-6
- 17. Update on IL-15
- 18. Update on IL-18
- 19. Update on OPG/anti-RANKL
- 20. Interleukin-32
- 21. Interleukin-13
- 22. IL-17: a new target in arthritis
- 23. Interleukin 21
- 24. The Interferons
- 25. Update - Inflammatory, angiogenic and homeostatis chemokines and their receptors
- Section III. Transcription factors and signalling molecules
- 26. Update on NFkB
- 27. Update on Jak/STATs
- 28. Suppressor of cytokine signalling (SOCS) proteins as therapeutic targets in rheumatoid arthritis
- 29. The various pathways of cytokine signalling - Wnt Signalling
- 30. NFAT
- 31. Signalling in osteoclasts and osteoblasts
- Section IV. Inflammatory mediators
- 32. Inflammatory Mediators: Update on Cyclooxygenases and PG Synthases
- Section V. Matrix molecules
- 33. Update on Matrix metalloproteinases
- 34. The ADAM family of MMPs
- Section VI. Targeted therapies in human and experimental rheumatic diseases
- 35. Update on proinflammatory cytokine blockade in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
- 36. Update on targeted therapy in psoriatic arthritis
- 37. Update on ankylosing spondylitis
- 38. Early Arthritis - Update
- 39. Juvenile arthritis - Update
- 40. Update - Systemic Lupus Erythmatosus
- 41. Vasculitis - update
- 42. Myositis - update
- 43. TNF-blockade in orphan rheumatic diseases
- 44. Overview of the safety of TNF inhibitors
- 45. Anti-CD20
- 46. CTLA-4Ig
- 47. Anti-IL6R
- 48. Anti-CD3 antibody - An History of successful immune interventions
- 49. Alefacept
- 50. Anti-VLA-4
- 51. Anti-IL-15
- 52. Clinical prospects of MAPK inhibitors
- 53. Clinical Prospects of NFkappaB Inhibitors to Advance Targeted Therapies in Rheumatology
